TY - JOUR
T1 - Landiolol for managing atrial fibrillation in intensive care.
AU - Rehberg, S
AU - Joannidis, M
AU - Whitehouse, T
AU - Morelli, A
PY - 2018/1
Y1 - 2018/1
N2 - Landiolol is an injectable ultrashort acting beta-blocker with high beta1 selectivity indicated for heart rate control of atrial fibrillation in the emergency and critical care setting. Accordingly, landiolol is associated with a significantly reduced risk of arterial hypotension and negative inotropic effects. Based on this particular profile along with the clinical experience in Japan for more than a decade landiolol represents a promising agent for the management of elevated heart rate and atrial fibrillation in intensive care patients even with catecholamine requirements. This article provides a review and perspective of landiolol for heart rate control in intensive care patients based on the current literature.
AB - Landiolol is an injectable ultrashort acting beta-blocker with high beta1 selectivity indicated for heart rate control of atrial fibrillation in the emergency and critical care setting. Accordingly, landiolol is associated with a significantly reduced risk of arterial hypotension and negative inotropic effects. Based on this particular profile along with the clinical experience in Japan for more than a decade landiolol represents a promising agent for the management of elevated heart rate and atrial fibrillation in intensive care patients even with catecholamine requirements. This article provides a review and perspective of landiolol for heart rate control in intensive care patients based on the current literature.
UR - http://europepmc.org/abstract/med/30188960
U2 - 10.1093/eurheartj/sux039
DO - 10.1093/eurheartj/sux039
M3 - Article
C2 - 30188960
VL - 20
SP - A15-A18
JO - European heart journal supplements : journal of the European Society of Cardiology
JF - European heart journal supplements : journal of the European Society of Cardiology
IS - A
ER -